# Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

> **NCT03300050** · PHASE1 · COMPLETED · sponsor: **PATH** · enrollment: 65 (actual)

## Conditions studied

- Influenza
- Vaccine

## Interventions

- **BIOLOGICAL:** cH8/1N1 LAIV
- **BIOLOGICAL:** AS03-adjuvanted cH5/1N1 IIV
- **BIOLOGICAL:** cH5/1N1 IIV
- **BIOLOGICAL:** AS03-adjuvanted cH8/1N1 IIV
- **BIOLOGICAL:** Normal saline
- **BIOLOGICAL:** Phosphate buffered saline (PBS)

## Key facts

- **NCT ID:** NCT03300050
- **Lead sponsor:** PATH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-10
- **Primary completion:** 2018-04-24
- **Final completion:** 2019-08-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03300050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03300050, "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03300050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*